1 October 2020: UDG Healthcare plc (the "Company"), a leading international healthcare services provider, is pleased to announce the appointment of Ms Anne Whitaker as a Non-Executive Director of the Company with effect from today. In addition, in connection with the previously announced Chair succession, the Company also announces changes to the composition of its Board Committees, as outlined below.
Anne has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech, and speciality pharma companies. She is currently the Chief Executive Officer of Aerami Therapeutics (formerly Dance Biopharm Holdings, Inc.), a clinical stage pharmaceutical and medical device company, having held this role since October 2018. She also served as Chief Executive Officer at KNOW Bio, LLC and Novoclem Therapeutics, Inc., a wholly owned subsidiary of KNOW Bio from February 2017 until April 2018. Previously, Anne was Executive Vice President and Company Group Chairman at Bausch Health, where she was responsible for overseeing its Global Branded Pharmaceutical Business. Prior to that, Anne served as President and Chief Executive Officer of Synta Pharmaceuticals. She also served as President, North America Pharmaceuticals at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations for the region and held several commercial leadership roles at GlaxoSmithKline. More recently, Anne served as a Non-Executive Director for the London listed plc, Vectura Group plc.
Anne is an Independent Director of Cree, Inc., a NASDAQ traded company, and NYSE-listed Mallinckrodt plc. She is also a Trustee for the University of North Alabama.
Commenting on her appointment, Shane Cooke, Independent Non-Executive Chair said: "We are delighted that Anne has agreed to join the UDG Board. Her broad experience in the US pharmaceutical market will further inform and support our strategic development in this market, while her recent tenure on the board of a UK plc means she is familiar with the UK corporate governance framework."
Chair Succession and Committee Changes
Further to the announcement on 5 August 2020, UDG is pleased to announce that with effect from today, Shane Cooke assumes the role of Independent Non-Executive Chair of the Company, succeeding Peter Gray who retired from the Company on 30 September 2020. Also, with effect from today, Shane succeeds Peter as Chair of the Nominations, Governance and Sustainability Committee and also joins the Remuneration Committee.
Shane Cooke commented: "I would like to thank Peter for his outstanding service to UDG since he joined the Board as a Non-Executive Director in 2004 and in particular, for his excellent leadership and stewardship of the UDG Board as Chair since 2012. His business experience, wisdom and judgement have been instrumental in shaping the Company's strategy over the years and on behalf of myself and my Board colleagues, we wish Peter the very best for the future."
Brendan McAtamney, UDG Healthcare's Chief Executive Officer, commented: "On behalf of the Senior Executive Team, all of our colleagues across UDG and myself personally, I would like to congratulate Peter on his retirement and thank him most sincerely for his significant contribution to UDG over the last 16 years. As our Company strategy evolved, Peter helped shape and navigate the execution of this strategy, particularly in his capacity as Chair of the Board since 2012."
Peter Gray commented: "As I step down from UDG, I'd like to welcome Anne Whitaker, our fourth female board member, and to thank my excellent Board colleagues and a great management team for making my job as Chair as enjoyable as it was interesting."
This announcement is made in accordance with Listing Rule 9.6.11.
No further information is required to be disclosed pursuant to Listing Rule 9.6.11 and 9.6.13.
For further information, please contact:
UDG Healthcare plc
General Counsel & Company Secretary
+353 (1) 468 9000
Business / Financial media:
Lisa Kavanagh / Jack Hickey / Eavan Gannon
Tel: + 44-207-250-1446
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a FTSE 250 global leader in the healthcare advisory, communications, commercial, clinical and packaging services industries. UDG employs 9,000 people across operations in 29 countries, delivering services in over 50 countries.
Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services which enable over 300 healthcare companies from large pharmaceutical to small biotech to bring their products to market.
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three business areas: Advisory, Communications and Commercial & Clinical. The division focuses on supporting patients to access and adhere to their medications and educating and communicating effectively with healthcare professionals and patients on these products at all stages of the product life cycle. Ashfield provides strategic consulting, advisory services, patient solutions, scientific and creative communications, PR, on-demand advertising services, field and contact centre sales teams, and medical information and event management services.
Sharp is a global leader in contract commercial packaging, clinical, manufacturing and technology services for the pharmaceutical and biotechnology industries, operating from eight state-of-the-art facilities in the US and Europe.
For more information, please go to: www.udghealthcare.com